Compare Gilead Sciences, Inc. (GILD) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs BlackRock TCP Capital Corp — how do they compare? Gilead Sciences, Inc. trades at $149.66 (market cap $182.40B), while BlackRock TCP Capital Corp trades at $3.99 (market cap $337.71M). The key difference: Gilead Sciences, Inc. is far larger — about 540.1× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (18.88%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and BlackRock TCP Capital Corp for 88 Days on average.
| GILD | TCPC | |
|---|---|---|
Market Cap | $182.40B | $337.71M |
Volume | 4,469,821 | 436,109 |
Sector | Health | Financials |
52-Week High | $155.80 | $6.20 |
52-Week Low | $116.74 | $3.13 |
Typical Hold Time | 111 Days | 88 Days |
Enterprise Value | $205.46B | $1.09B |
Dividend Yield | 2.23% | 18.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
TCPC trades at $4.01, up 1.78% today, with a bullish technical signal from moving averages. The company reported Q2 2026 earnings of $0.22 per share, beating expectations, and announced a $523 million portfolio sale to reduce leverage. However, revenue and net income remain negative, with a net income margin of 118.75% in 2026 indicating significant losses relative to revenue. The stock is trading below book value with a P/B of 0.61.
The outlook is mixed: strategic actions like portfolio sales may improve financial health, but persistent negative earnings and a class action lawsuit pose risks. Analyst sentiment is cautious with a 30.77% buy rating. Investors should weigh the potential for operational turnaround against ongoing profitability challenges and legal overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
